{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T01:34:15Z","timestamp":1785202455974,"version":"3.55.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1111\/igc.0b013e3181a3d100","type":"journal-article","created":{"date-parts":[[2010,12,3]],"date-time":"2010-12-03T13:40:58Z","timestamp":1291383658000},"page":"1166-1176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Efficacy of Human Papillomavirus Vaccines"],"prefix":"10.1016","volume":"19","author":[{"given":"Lidia Rosi","family":"Medeiros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela Dornelles","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria In\u00eas","family":"Da Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Clarisse","family":"Bozzetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roselaine Ruviaro","family":"Zanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/IGC.0b013e3181a3d100_bib5","unstructured":"WHO. Initiative for vaccine research. Human Papillomavirus Infections and Cervical Cancer. Available at http:\/\/www.who.int\/vaccine_research\/diseases\/hpv\/en\/. Accessed March 11, 2007."},{"key":"10.1111\/IGC.0b013e3181a3d100_bib10","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","article-title":"Epidemiologic classification of human papillomavirus types associated with cervical cancer","volume":"348","author":"Munox","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1363\/3600604","article-title":"Sexually transmitted diseases among American youth: incidence and prevalence estimates","volume":"36","author":"Weinstock","year":"2004","journal-title":"Perspect Sex Reprod Health"},{"issue":"Suppl. 1","key":"10.1111\/IGC.0b013e3181a3d100_bib20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/01.gco.0000216315.72572.fb","article-title":"The development of cervical cancer and its precursors: what is the role of human papillomavirus infection?","volume":"18","author":"Cox","year":"2006","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"Suppl. 2","key":"10.1111\/IGC.0b013e3181a3d100_bib25","first-page":"1","article-title":"HPV vaccine and its recommendations, 2007","volume":"56","author":"Zimmerman","year":"2007","journal-title":"J Fam Pract"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib30","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1001\/jama.296.6.640","article-title":"CDC panel backs routine HPV vaccination","volume":"296","author":"Kuehn","year":"2006","journal-title":"JAMA"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib35","unstructured":"CDC. FDA licenses quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil) for the prevention of cervical cancer and other diseases in females caused by human papillomavirus. Office of Oncology Available at: http:\/\/www.fda.gov\/cder\/Offices\/OODP\/whatsnew\/gardasil. Accessed March 13, 2007."},{"key":"10.1111\/IGC.0b013e3181a3d100_bib40","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases (The FUTURE I Group)","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib45","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib50","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/01.AOG.0000192397.41191.fb","article-title":"Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia","volume":"107","author":"Mao","year":"2006","journal-title":"Obstet Gynecol"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib55","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4.5 years of bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib60","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomized controlled","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib65","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.298.7.743","article-title":"Effects of human papillomavirus 16\/18 L1 viruslike particle vaccine among young women with preexisting infection","volume":"15","author":"Hildesheim","year":"2007","journal-title":"JAMA"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib70","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0020-7292(00)90001-8","article-title":"FIGO staging classifications and clinical practice guidelines of gynaecologic cancers. FIGO committed on Gynecologic Oncology","volume":"70","author":"Benedet","year":"2000","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomised clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib80","doi-asserted-by":"crossref","first-page":"42Y","DOI":"10.1136\/bmj.323.7303.42","article-title":"Systematic reviews in health care: assessing the quality of controlled clinical trials","volume":"323","author":"J\u00fcni","year":"2001","journal-title":"BMJ"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib85","unstructured":"Phillips B, Ball C, Sackett D, et al. Oxford Centre for Evidence-Based Medicine Level of Evidence Grades of Recommendations (May 2001). Available at http:\/\/www.cebm.net\/index.asp?.0=1025. Accessed October 31, 2007."},{"key":"10.1111\/IGC.0b013e3181a3d100_bib90","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(99)04149-5","article-title":"Improving the quality of reports of meta-analysis of randomized controlled trial: the QUORUM statement","volume":"354","author":"Moher","year":"1999","journal-title":"Lancet"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib95","series-title":"Systematic Reviews in Health Care: Meta-Analysis in Contex.","first-page":"248","article-title":"Systematic reviews in health care. Assessing the quality of randomized controlled trials.","author":"J\u00fcni","year":"2001"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib100","series-title":"Methods for Meta Analysis in Medical Research.","first-page":"73","article-title":"Random effects methods for combining study estimates.","author":"Sutton","year":"2000"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib105","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/bmj.323.7304.101","article-title":"Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis","volume":"323","author":"Sterne","year":"2001","journal-title":"BMJ"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib110","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib115","series-title":"Designing Clinical Research and Epidemiologic Approach.","first-page":"157","article-title":"Designing and experiment: clinical trial II.","author":"Grady","year":"2001"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib120","series-title":"Systematic Reviews in Health Care: Meta-analysis in Context.","first-page":"69","article-title":"Identifying randomized trials.","author":"Lefebvre","year":"2001"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib125","series-title":"Version 1.0 for Windows. In Review Manager (RevMan). Version 4.2 for Windows.","year":"2003"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib130","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jadohealth.2007.02.015","article-title":"Immunization for early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant","volume":"40","author":"Pedersen","year":"2007","journal-title":"J Adolesc Health"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib135","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1089\/10430340460745757","article-title":"Therapeutic vaccination MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, CIN 3) associated with infection by oncogenic human papillomavirus","volume":"15","author":"Corona Gutierrez","year":"2004","journal-title":"Hum Gen Ther"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib140","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1034\/j.1600-0412.2003.00086.x","article-title":"Eligibility and willingness of young Icelandic women to participate in a HPV vaccination trial","volume":"82","author":"Gudmundsd\u00f3ttir","year":"2003","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib145","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s00262-004-0501-4","article-title":"Phase I\/II trial of immunogenicity of a human papillomavirus (HPV type) 16 E7 protein\u2013based vaccine in women with oncogenic HPV positive cervical intraepithelial neoplasia","volume":"53","author":"Hallez","year":"2004","journal-title":"Cancer Immunol Immunother"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib150","first-page":"2103","article-title":"Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7","volume":"4","author":"Steller","year":"1998","journal-title":"Clin Can Res"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib155","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/sj.cgt.7700937","article-title":"Regression of papillomavirus high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine","volume":"13","author":"Garc\u00eda-Hern\u00e1ndez","year":"2006","journal-title":"Cancer Gene Ther"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib160","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1016\/j.vaccine.2005.02.019","article-title":"Immune responses induced by lower airway mucosal immunization with a human papillomavirus type 16 virus-like particle vaccine","volume":"23","author":"Nardelli-Haefliger","year":"2005","journal-title":"Vaccine"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib165","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/01.aids.0000226955.02719.26","article-title":"A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals","volume":"20","author":"Palefsky","year":"2006","journal-title":"AIDS"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib170","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0301-2115(03)00093-9","article-title":"Cervical response to vaccination against HPV 16 E7 in case of severe dysplasia","volume":"109","author":"Simon","year":"2003","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib175","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1136\/ijgc-00009577-200605000-00020","article-title":"Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial","volume":"16","author":"Fiander","year":"2006","journal-title":"Int J Gynecol Cancer"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib180","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1086\/323645","article-title":"Neutralization of human papillomavirus type 11 (HPV 11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlations with competitive radioimmunoassay titer","volume":"184","author":"Brown","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib185","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","article-title":"Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo controlled multicentre phase II efficacy trial","volume":"6","author":"Villa","year":"2005","journal-title":"Lancet"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib190","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60852-6","article-title":"Effects of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomized clinical trials","volume":"369","author":"Ault","year":"2007","journal-title":"Lancet"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib195","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0140-6736(07)60777-6","article-title":"Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomized clinical trials","volume":"369","author":"Joura","year":"2007","journal-title":"Lancet"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib200","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMoa020586","article-title":"A controlled trial of human a papillomavirus type 16 vaccine","volume":"347","author":"Koutski","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib205","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/sj.bjc.6603469","article-title":"High sustained efficacy of prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5 years of follow-up","volume":"95","author":"Villa","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib210","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus- like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomizes controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib215","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.2165\/00003495-200666090-00008","article-title":"Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil)","volume":"66","author":"Siddiqui","year":"2006","journal-title":"Drugs"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib220","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1016\/j.vaccine.2006.04.068","article-title":"Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16 and 18","volume":"24","author":"Villa","year":"2006","journal-title":"Vaccine"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib225","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/01.inf.0000253970.29190.5a","article-title":"Safety persistence immunogenicity of a quadrivalent human papillomavirus types 6,11,16, 18 L1 virus-like particle vaccine in preadolescents and adolescents","volume":"26","author":"Reisinger","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib230","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/376505","article-title":"Cellular immune responses to human papillomavirus (HPV)V16 L1 in healthy volunteers immunized with recombinant HPV-16 virus-like particles","volume":"188","author":"Pinto","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib235","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/S0140-6736(04)17410-2","article-title":"Vaccination against human papillomaviruses shows great promise","volume":"364","author":"Lehtinen","year":"2004","journal-title":"Lancet"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib240","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/S0140-6736(07)60947-7","article-title":"Papillomavirus vaccines in perspective","volume":"369","author":"Kahn","year":"2007","journal-title":"Lancet"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib245","doi-asserted-by":"crossref","first-page":"451Y","DOI":"10.1016\/j.virol.2006.06.021","article-title":"Cellular immune responses to HPV-8, 31, and 53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles","volume":"353","author":"Pinto","year":"2006","journal-title":"Virology"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib250","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(05)70141-8","article-title":"The end for genital human papillomavirus infections?","volume":"6","author":"Stanley","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib255","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMe078060","article-title":"HPV vaccinationVmore answer, more questions","volume":"356","author":"Sawaya","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib260","first-page":"5205","article-title":"Vaccinia-expressed human papillomavirus 16 and 18 E6 and E7 as a therapeutic vaccination for vulva and vaginal intra-epithelial neoplasia","volume":"9","author":"Daldwin","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib265","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJM200304033481418","article-title":"A human papillomavirus type 16 vaccine","volume":"348","author":"Duggirala","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib270","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1056\/NEJMe020121","article-title":"The beginning of the end for cervical cancer?","volume":"347","author":"Crum","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib275","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1258\/095646206778145550","article-title":"Enrolment of 22,000 adolescent women to cancer registry follow-up for long term human papillomavirus vaccine efficacy: guarding against guessing","volume":"17","author":"Lehtinen","year":"2006","journal-title":"Int J STD AIDS"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib280","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/01.olq.0000253337.62932.29","article-title":"Potential impact of human papillomavirus vaccines on public STD clinical workloads and on opportunities to diagnose and treat other sexually transmitted diseases","volume":"34","author":"Dempsey","year":"2007","journal-title":"Sex Transm Dis"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib285","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1158\/1055-9965.EPI-06-0846","article-title":"Incidence and duration of cervical human papillomavirus 6, 11, 16 and 18 infections in young women: an evaluation from multiple analytic perspectives","volume":"16","author":"Insinga","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib290","series-title":"Practical Statistics for Medical Research.","author":"Altman","year":"1999"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib295","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1016\/j.vaccine.2006.06.005","article-title":"Enhanced humoral and memory B cellular immunity using HPV 16\/18 L1 VLP vaccine formulated with MPL\/aluminium salt combinations (AS04) compared to aluminium salt only","volume":"24","author":"Giannini","year":"2006","journal-title":"Vaccine"},{"issue":"Suppl. 1","key":"10.1111\/IGC.0b013e3181a3d100_bib300","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/01.gco.0000216317.10690.8f","article-title":"Understanding and overcoming barriers to human papillomavirus vaccine acceptance","volume":"18","author":"Zimet","year":"2006","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib305","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1056\/NEJMoa053284","article-title":"Condom use and the risk of genital human papillomavirus infection in young women","volume":"354","author":"Winer","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib310","doi-asserted-by":"crossref","first-page":"418Y","DOI":"10.1002\/ijc.11719","article-title":"Cervical cancer as a priority for prevention in different world region: an evaluation using years of life lost","volume":"109","author":"Yang","year":"2004","journal-title":"IntJ Cancer"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib315","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0140-6736(07)61416-0","article-title":"Human papillomavirus and cervical cancer","volume":"370","author":"Schiffman","year":"2007","journal-title":"Lancet"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib320","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1503\/cmaj.070948","article-title":"Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized control trials","volume":"177","author":"Rambout","year":"2007","journal-title":"CMAJ"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib325","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jcv.2006.12.009","article-title":"Review of current knowledge of HPV vaccination: an appendix to the European guidelines for quality assurance in cervical cancer screening","volume":"38","author":"Arbyn","year":"2007","journal-title":"J Clin Virol"},{"key":"10.1111\/IGC.0b013e3181a3d100_bib330","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/j.1525-1438.2007.01129.x","article-title":"ESGO stamen on cervical cancer vaccination","volume":"17","author":"Vergote","year":"2007","journal-title":"Int J Gynecol Cancer"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2FIGC.0b013e3181a3d100","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24155132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24155132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:05:36Z","timestamp":1753229136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24155132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":66,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["S1048891X24155132"],"URL":"https:\/\/doi.org\/10.1111\/igc.0b013e3181a3d100","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Human Papillomavirus Vaccines","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/IGC.0b013e3181a3d100","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright Copyright \u00a9 2009 by IGCS and ESGO.","name":"copyright","label":"Copyright"}]}}